Perspective & Commentary
From Rules to Results: What a Decade of Medical Device Outcomes Taught Us About Screening
In medical devices, the path to market is often shorter and more visible than in therapeutics, but that does not make investing straightforward. The challenge shifts earlier from science to commercialization, reimbursement, and buyer fit, and survival is far more common than meaningful liquidity. Can disciplined screening improve angel outcomes? Alex Pederson and Yaniv Sneor, Mid Atlantic Bio Angels.
Read Article